Key Account Management Europe Summit

eyeforpharma29 - 30 November 2010, London, UK.
eyeforpharma's Key Account Management Europe Summit, taking place in London in November, includes a half-day workshop led by David Wright, director of Imonic, a leading expert on KAM and chair of the KAM stream at SFE Europe 2010 in Barcelona. Following the success of the SFE event, which attracted over 200 delegates to the KAM element alone, David's detailed discussions with Kate Eversole and eyeforpharma contributed to the formulation of the new London-based KAM summit, which we are delighted to see includes an impressive program of speakers from both pharma and healthcare providers.

The November workshop will focus on providing practical solutions, and will address in particular the following:

  • How to get and keep commitment from your leadership team, not just a token lip-service acceptance (e.g., comments such as "You can implement KAM but you can't change the organizational structure or the incentive scheme, and we're not investing in new IT systems!"). How do you prove that the ‘old model' is broken and no longer works? How do you exploit and communicate the benefits of KAM and get the investments and commitments you need to make a success of KAM in your organization?
  • How to measure KAM effectively. The temptation is to still track 'calls per day', but the emphasis with KAM is on quality, not quantity, so other metrics become relevant. What are these metrics? How do they correlate to sales and how can they be implemented?
  • Why is effective planning critical to the success of KAM? How do you get the balance right between time allocated to planning and time in the field? What constitutes best practice as far as planning is concerned, and how can effective account strategies be developed and implemented?
  • How to align IT systems to support best practice in KAM and how to develop a clear statement of requirements and assess the gaps.
  • What are the account management skills critical for KAM success? How do we achieve a high quality of engagement from account teams?
  • How to use a customer feedback program to improve success with KAM and identify what customers want and evaluate their feedback.

Imonic's David Wright will offer unique insights into how pharma should confront these challenges in 2011, with practical advice and solutions based on Imonic's experiences of KAM implementation in pharma and for over 20 years in other sectors.

For further information and registration, please visit:
http://www.eyeforpharma.com/kameu/

About eyeforpharma
eyeforpharma is a division of a private company headquartered in London, UK. We have offices in New York, South Africa and Australia. We have grown by at least 30% per year since our creation in 2002.

We are the sum of the quality of those people and pride ourselves on recruiting not only the professional and innovative but the personable. That is why so many of our contacts are now our friends aswell as our trusted advisors. It is this level of dialogue that we seek to promote throughout the pharma world.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]